Business Context and Reporting Period
Company: Envue Medical, Inc. (formerly NanoVibronix, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: The Company operates through two segments: NanoVibronix (non-invasive biological response-activating devices for wound healing and pain therapy) and ENvue (enteral feeding systems). Following the ENvue Merger in February 2025, the Company has consolidated operations. Manufacturing for NanoVibronix was temporarily halted due to the war in Israel and relocated to the U.S., with production re-established in August 2026.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (in thousands) |
|---|---|
| Revenue | $892 |
| Gross Loss | $(321) |
| Operating Loss | $(9,185) |
| Net Loss | $(8,721) |
| Net Loss Available to Common Stockholders | $(34,785) |
| Cash and Cash Equivalents (End of Period) | $1,084 |
| Net Cash Used in Operating Activities | $(7,003) |
| Total Debt (Current Loan) | $1,080 |
| Accumulated Deficit | $(124,448) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 41.3% to $892 (from $1,519 in 2025), primarily due to the temporary halt in NanoVibronix production caused by the war in Israel. This was partially offset by a 100% increase in ENvue revenue to $303.
- Gross Margin Deterioration: The Company shifted from a gross profit of $334 in the prior year to a gross loss of $(321). This was driven by $280 in amortization of intangible assets from the ENvue Merger, discounted ENvue system sales to expand the installed base, and inventory write-downs of $163.
- Expense Increases:
- Selling & Marketing: Increased 92.2% to $1,924 due to ENvue commercialization and UroShield expansion into the UK.
- General & Administrative: Increased 64.6% to $5,916, driven by a full six months of ENvue operations, stock-based compensation ($2,048), and severance costs.
- Equity Transactions: Significant non-cash "deemed dividends" of $23,556 were recorded due to down-round features on Series H Preferred Stock, drastically increasing the net loss attributable to common stockholders.
Outlook, Risks, and Contingencies
- Going Concern: The Company has substantial doubt about its ability to continue as a going concern for the next 12 months due to recurring losses and negative cash flows. It relies on additional financing to fund operations.
- Liquidity Strategy: On August 12, 2026 (subsequent event), the Company entered into a committed equity facility with Alpha Capital Anstalt to sell up to $50 million of common stock. Proceeds are required to be used 40% to redeem Series X Preferred Stock.
- Nasdaq Compliance: The Company received a Staff Determination Letter regarding non-compliance with the minimum $1.00 bid price requirement. Due to a recent reverse stock split, the Company is not eligible for a standard compliance period and has requested a hearing to avoid delisting.
- Legal Contingency: An arbitration award of approximately $2,319 (including interest) was accrued regarding a dispute with Protrade Systems, Inc. The Company's appeal was dismissed in March 2026, and the Company is reviewing alternatives.
- Regulatory: The Company voluntarily withdrew its 510(k) application for the PainShield MD Plus product due to inaccuracies and intends to halt future sales of that specific product.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.08 million cash balance against the $7.0 million operating cash burn rate for the six-month period.
- Equity Facility Terms: Review the August 12, 2026, Common Shares Purchase Agreement to understand the pricing mechanism (90% of VWAP) and the mandatory 40% use of proceeds for preferred stock redemption.
- Nasdaq Status: Monitor the outcome of the hearing regarding the minimum bid price deficiency and the potential for delisting.
- Production Recovery: Confirm the volume and revenue impact of the re-established NanoVibronix manufacturing operations in the U.S. post-August 2026.
- Preferred Stock Dilution: Assess the impact of the Series H Preferred Stock down-round features and the potential for further deemed dividends on common shareholder value.